A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

Laure Elens, Rachida Bouamar, Dennis A. Hesselink, +4

Clinical Chemistry

A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation

Nauras Shuker, Rachida Bouamar, Ron H. N. van Schaik, +8

American Journal of Transplantation

UrologyTransplantationKidney TransplantBody‐weight‐based Tacrolimus DosingHigher Tacrolimus Dose +13

Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials

Rachida Bouamar, Nauras Shuker, Dennis A. Hesselink, +5

American Journal of Transplantation

Transplant RejectionUrologyTransplantationKidney TransplantKidney Transplantation +7

Follicular T helper cells and humoral reactivity in kidney transplant patients

Gretchen N. de Graav, M. Dieterich, Dennis A. Hesselink, +14

Clinical & Experimental Immunology

Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients

Laure Elens, Dennis A. Hesselink, Rachida Bouamar, +8

Therapeutic Drug Monitoring

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

Laure Elens, Rachida Bouamar, Dennis A. Hesselink, +3

Pharmacogenetics and Genomics

Genetic Polymorphisms in ABCB1 Influence the Pharmacodynamics of Tacrolimus

Ramin Vafadari, Rachida Bouamar, Dennis A. Hesselink, +5

Therapeutic Drug Monitoring

Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation

Rachida Bouamar, Dennis A. Hesselink, Ron H. N. van Schaik, +4

Therapeutic Drug Monitoring

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose

Louise M. Andrews, Brenda C. M. de Winter, Jiangtao Tang, +6

Transplantation Direct

CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance

Nilufar Pashaee, Rachida Bouamar, Dennis A. Hesselink, +4

Therapeutic Drug Monitoring